FDMT

10.1705.13%
SC

Shawn Cline Tomasello

Independent Director

Ms. Shawn Cline Tomasello, BS, MBA, serves as an Independent Director at Cabaletta Bio, Inc. since July 2023. She was Independent Chairwoman of Gamida Cell Ltd. since March 21, 2023 until 2024. She served as an Independent Director at AlloVir, Inc. since March 2022. She has been an Independent Director of TCR2 Therapeutics Inc. since February 3, 2021. She joined as an Independent Director of 4D Molecular Therapeutics, Inc. from November 2020. Ms. Tomasello was an Independent Director of Gamida Cell Ltd. since June 4, 2019 until 2024. She served as an Independent Director of Principia Biopharma Inc. since August 30, 2019 until September 28, 2020. Ms. Tomasello served as an Independent Director at Abeona Therapeutics Inc. since April 15, 2020 until September 28, 2020. She had been Independent Non-Executive Director of Mesoblast Limited since July 11, 2018 until August 18, 2022. She served as the Chief Commercial Officer of Commercial and Medical Affairs at Kite Pharma, Inc. since December 21, 2015 until July 2018, where she played a pivotal role in its acquisition in 2017 by Gilead Sciences. Ms. Tomasello built Kites commercial and medical affairs operations. Prior to joining Kite, Ms. Tomasello served as the Chief Commercial Officer of Commercial and Medical Affairs at Pharmacyclics Inc. (also known as Pharmacyclics LLC) since August 18, 2014 until August 2015 and was previously the President of the Americas, hematology and oncology for Celgene Corporation. She has broad commercial and medical affairs experience in the biotechnology industry, she has successfully built and led commercial operations at several companies, including Pharmacyclics, Celgene and Genentech. Prior to Pharmacyclics, Ms. Tomasello served in leading commercial roles with multiple major pharmaceutical companies, including Celgene as President of the Americas Hematology and Oncology, where she led five successful product launches encompassing 11 indications and played a critical role in acquisitions. She served as Senior Vice President and General Manager of Hematology & Oncology at Celgene Corporation. She was employed at Celgene Corporation from April 2005 to August 2014 and was employed initially as the Vice President of sales and training. In addition, she was instrumental in strategic decision making regarding global expansion and M&A evaluations which led to the acquisition and integration of Pharmion Corporation, Gloucester Pharmaceuticals, Inc. and Abraxis Biosciences, Inc. She was employed at Genentech Inc. from 1989 to 2005, where she served as the National Director for Rituxan responsible for all in-line and new indications for the hematology commercial organization from 2003 to April 2005. In addition, she also held positions at Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble in her career. She served as a Director of UroGen Pharma Ltd. since July 10, 2018 until June 08, 2022. She has been a Director at Centrexion Therapeutics Corporation since June 26, 2017. She served as a Director of Clementia Pharmaceuticals Inc. since joining on July 5, 2018. She served as a Director of Diplomat Specialty. She served as a Non-Executive Director of Oxford BioTherapeutics Ltd. She served as a Board Member of BioNJ Inc. She had been Independent Director of Diplomat Pharmacy, Inc. since October 6, 2015 until February 10, 2020. She served many years in the pharmaceutical manufacturing industry. Ms. Tomasello received her B.S. in marketing from the University of Cincinnati in 1982 and her MBA from Murray State University in Kentucky in 1989.

Positions